Glaukos Corporation (GKOS) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $41.16 with a loss of -0.06 points or -0.15%. The net money flow was $0.32 million and the up/down ratio was 2.76. Approximately $0.5 million was the inflow in upticks and $0.18 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of 6.06%.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Glaukos Corporation rose by 5.44% in the last five trading days and 19.85% for the last 4 weeks. Glaukos Corporation is up 23.08% in the last 3-month period. Year-to-Date the stock performance stands at 19.85%. Glaukos Corporation (NYSE:GKOS) witnessed a decline in the market cap on Wednesday as its shares dropped 0.27% or 0.11 points. After the session commenced at $41.35, the stock reached the higher end at $41.4399 while it hit a low of $40.82. With the volume soaring to 515,368 shares, the last trade was called at $41.11. The company has a 52-week high of $41.4399. The company has a market cap of $1,379 million and there are 33,549,174 shares in outstanding. The 52-week low of the share price is $14.25.
Company has reported several Insider transactions to the SEC, on Jan 13, 2017, Richard L Harrison (CFO & Treasurer) sold 20,634 shares at 40.01 per share price.On Jan 13, 2017, Chris M. Calcaterra (Chief Commercial Officer) sold 18,136 shares at 40.01 per share price.On Jan 11, 2017, Thomas William Burns (Chief Executive Officer) sold 40,000 shares at 37.60 per share price.
Glaukos Corp Last issued its quarterly earnings results on Nov 10, 2016. The company reported $0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.00. The company had revenue of $29.60 million for the quarter, compared to analysts expectations of $27.47 million. The companys revenue was up 55.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Upgraded by Stifel on Jan 6, 2017 to Buy, Raises Price Target to $ 45 from a previous price target of $42 .
Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California.